Printer Friendly

FDA schedules Advisory Panel meeting for review of BioMimetic's Augment Bone Graft PMA.

M2 PHARMA-February 1, 2011-FDA schedules Advisory Panel meeting for review of BioMimetic's Augment Bone Graft PMA(C)2011 M2 COMMUNICATIONS

1 February 2011 - US BioMimetic Therapeutics Inc (NASDAQ: BMTI) said yesterday that the US Food and Drug Administration (FDA) has tentatively scheduled an Orthopedic and Rehabilitation Devices Panel meeting on 12 May 2011 to review the company's Premarket Approval (PMA) application for Augment Bone Graft for the treatment of foot and ankle fusions.

If the panel determines that the product's benefits outweigh any potential risks, the company expects approval of Augment by the FDA within three to six months after the panel date, BioMimetic said.

To date, nearly 650 patients have been treated in Augment orthopedic clinical trials over the past four years, said Dr Samuel Lynch, BioMimetic's president and CEO. Moreover, GEM 21S, a nearly identical product, has proven safe and effective for treatment of periodontal bone and soft tissue defects during its five years of commercial use, added Dr Lynch.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 1, 2011
Words:173
Previous Article:Oragenics to start second Phase I study of SMaRT Replacement Therapy.
Next Article:FDA grants Fast Track designation to Onyx's carfilzomib in multiple myeloma.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters